Screener
Icahn Enterprises IEP Pharma — Total Costs & Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| Selling, general and administrative | 2 | 41 | 109 | 13 | 5 | 11 | 14 | 8 | 203 |
| Restructuring, net | — | — | — | 1 | — | — | 1 | — | 2 |
| Interest expense | 2 | 32 | — | 3 | — | — | — | 84 | 121 |
| 9 | 2,705 | 368 | 95 | 28 | 40 | 24 | 92 | 3,361 | |
| (Loss) income before income tax benefit | (312) | 40 | (14) | (5) | (1) | (2) | (7) | (85) | (386) |
| Income tax (expense) benefit | — | (6) | 4 | (1) | — | — | — | 1 | (2) |
| Net (loss) income | (312) | 34 | (10) | (6) | (1) | (2) | (7) | (84) | (388) |
| Less: net (loss) income attributable to non-controlling interests | (74) | 41 | — | — | — | — | — | — | (33) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — total costs & expenses?
- Icahn Enterprises (IEP) reported pharma — total costs & expenses of $24M in Q2 2026.
- How has Icahn Enterprises's pharma — total costs & expenses changed year-over-year?
- Icahn Enterprises's pharma — total costs & expenses decreased by 20.0% year-over-year, from $30M to $24M.
- What is the long-term trend for Icahn Enterprises's pharma — total costs & expenses?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — total costs & expenses has grown at a 5.5% compound annual growth rate (CAGR), from $88M to $109M.
- What does pharma — total costs & expenses mean?
- Represents the total aggregate expenditures incurred by the Pharma segment to support its operations, including cost of goods sold, research and development, and administrative overhead. This metric provides insight into the overall cost structure and operational efficiency of the business unit. Monitoring this helps investors assess the segment's ability to manage its expense base relative to revenue generation.
Ask your AI about Icahn Enterprises's pharma — total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude